Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 34,838

Document Document Title
WO/2018/011201A1
The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is -CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alky...  
WO/2018/010622A1
Provided are a preparation method for a crystalline form of the compound represented by formula (A), as well as a method for preparation thereof, a composition thereof, and an application thereof in preparing an angiotensin II receptor a...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/010514A1
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method therefor, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The comp...  
WO/2018/013772A1
Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a...  
WO/2018/011746A1
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2018/011747A1
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2018/011376A1
A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. ...  
WO/2018/011673A2
The present disclosure relates to 1, 3, 5-dioxazine derivatives of formula (I) capable of reducing or eliminating hydrogen sulfide and other objectionable sulfides from oil field produced hydrocarbon fluids such as petroleum, fuel oil, g...  
WO/2018/009505A1
The present disclosure generally relates to compounds of formula (I), wherin R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use....  
WO/2018/007973A2
Disclosed is a new process and intermediates for preparing benzoxazepines of Formula (I): (I) wherein Q is, and A, L, B, RA and m are as defined herein.  
WO/2018/009638A1
Multifunctional inhibitors of mTOR, MEK, and PI3K and compositions containing the same are disclosed. Methods of using the multifunctional inhibitors in the treatment of diseases and conditions wherein inhibition of one or more of mTOR, ...  
WO/2018/009622A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2018/008718A1
[Problem] To provide an organic compound having excellent characteristics, which exhibits, as a material for organic electroluminescent elements having high efficiency and high durability, excellent electron injection/transport performan...  
WO/2018/009609A1
The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I. Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceut...  
WO/2018/009602A2
The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyra...  
WO/2018/009597A1
The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyra...  
WO/2018/008219A1
The present invention provides: a method for producing an amidoxime compound, wherein a nitrile compound and hydroxylamine and/or an acid salt of hydroxylamine are reacted with each other in a reaction solvent that contains an alcohol ha...  
WO/2018/008442A1
The purpose of the present invention is to provide: a π-conjugated compound exhibiting excellent light emission characteristics; an organic electroluminescent element using same; a display device; and an illumination device. Accordingly...  
WO/2018/002437A1
Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.  
WO/2018/004223A1
The present invention relates to: any one compound selected from the group consisting of pyridine-based compounds including an isoxazoline ring represented by Formula 1 and agriculturally acceptable salts thereof; a herbicide including t...  
WO/2018/002217A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer...  
WO/2018/003924A1
Provided is a novel pest control agent, especially a bactericide or a nematicide. An alkynylpyridine-substituted amide compound represented by formula (I) or a salt thereof; and a pest control agent which contains the compound or the sal...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/005963A1
Lipophilic prodrugs of 4-methylumbelliferone are incorporated into lipid based drug delivery systems (e.g., emulsions, micelles, liposomes and lipid particles). The formulations protect 4-methylumbelliferone from first pass hepatic metab...  
WO/2018/005591A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...  
WO/2018/003976A1
In agricultural and horticultural crop production, etc., damage by pests and the like remains devastating even today, and due to factors such as the occurrence of pests resistant to existing chemicals, there is a demand for the developme...  
WO/2018/004213A1
The present invention relates to a novel compound having an SMO inhibitory activity, wherein the novel compound exhibits an excellent anticancer effect through abilities of isoindolinone and quinazolinone derivative compounds to modulate...  
WO/2017/222950A1
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl ...  
WO/2017/220446A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benz oic acid (referred to herein as "BHBA-001"), which...  
WO/2017/220485A1
Compounds of the Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.  
WO/2017/222952A1
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of heteroaryl substitut...  
WO/2017/223473A1
Compounds that inhibit or reduce glucose transport and methods of using the compounds to treat cancer are provided herein.  
WO/2017/222083A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their p...  
WO/2017/220208A1
The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadi...  
WO/2017/222951A1
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl subs...  
WO/2017/223188A1
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.  
WO/2017/223178A1
Methods for treating or reducing the risk or severity of a hemorrhagic virus infection or certain other viral infections in a mammal that include administering a therapeutically effective amount of an IMPDH inhibitor selected from (S)-N-...  
WO/2017/223115A1
A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD 140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 ...  
WO/2017/216726A1
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a ph...  
WO/2017/218330A1
The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment...  
WO/2017/218633A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.  
WO/2017/218337A1
The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of ...  
WO/2017/218843A1
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formu...  
WO/2017/211733A1
Relating to processes for preparing suvorexant or its pharmaceutically acceptable salts through the formation of a cocrystal of (R)-benzyl 5-methyl-1,4-diazepane-1-carboxylate hydrochloridewith (R)-(+)-1,1,2-triphenyl-1,2-ethanediol ((R)...  
WO/2017/213910A1
The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.  
WO/2017/213252A1
The present invention provides a compound having excellent control efficacies against pests. Specifically, the present invention provides a compound represented by formula (I): (wherein: A is a single bond, etc.; m is any one integer of ...  
WO/2017/210966A1
An organic photoelectric material and an organic electroluminescent device comprising the organic photoelectric material. The organic photoelectric material is represented by formula I. R1 and R2 are independently selected from a hydroge...  
WO/2017/207432A1
This invention relates to pyrazolone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.  

Matches 1 - 50 out of 34,838